Welcome to the BioLogicTube jeo@biologicmedia.dk https://biologictube.dk/app/facebook en-us Visualplatform http://blogs.law.harvard.edu/tech/rss Welcome to the BioLogicTube episodic no https://biologictube.dk/app/facebook/files/rv0.0/sitelogo.gif https://biologictube.dk/app/facebook http://biologictube.dk/photo/7202172/bang-olufsen-beovision-11 <p><span>Bang &amp; Olufsen BeoVision 11 Smart TV Launch presented by CEO Tue Mantoni.<br><br>B&amp;O launched their new BeoVision 11 at a spectacular event in Copenhagen October 11 2012. With the music of Dansk Fløde, punk and art of television came together. Sound by Freezone and filmed by BioLogicMedia<br></span></p><p><a href="http://biologictube.dk/photo/7202172/bang-olufsen-beovision-11"><img src="http://biologictube.dk/4959050/7202172/71ba1e74d8a3bec87a2042ac2153b91a/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/7202172 Sat, 20 Oct 2012 12:01:14 GMT Bang & Olufsen BeoVision 11 Launch Event Bang Olufsen BeoVision 11 Smart TV Launch presented by CEO Tue Mantoni.BO launched their new BeoVision 11 at a spectacular event in Copenhagen October 11 2012. With the music of Dansk Fløde, punk and art of television came together. Sound by Freezone and filmed by BioLogicMedia Bang Olufsen BeoVision 11 Smart TV Launch presented by CEO Tue Mantoni.BO launched their new BeoVision 11 at a spectacular event in Copenhagen October 11 2012. With the music of Dansk Fløde, punk and art of television came together. Sound by... Welcome to the BioLogicTube 02:26 <p><span>Bang &amp; Olufsen BeoVision 11 Smart TV Launch presented by CEO Tue Mantoni.<br><br>B&amp;O launched their new BeoVision 11 at a spectacular event in Copenhagen October 11 2012. With the music of Dansk Fløde, punk and art of television came together. Sound by Freezone and filmed by BioLogicMedia<br></span></p><p><a href="http://biologictube.dk/photo/7202172/bang-olufsen-beovision-11"><img src="http://biologictube.dk/4959050/7202172/71ba1e74d8a3bec87a2042ac2153b91a/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> & 11 2012. B&O Bang BeoVision BioLogicMedia CEO Copenhagen Dansk Fløde Freezone Launch Mantoni. October Olufsen Smart Sound TV Tue With a and art at by came event filmed in launched music new of presented punk spectacular television the their together. http://biologictube.dk/photo/4959161/brain-prize-winners-2012-karen <p>The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel:<br /> ‘for their unique, world-leading contributions to our understanding of the genetic regulation of the development and functioning of the ear, and for elucidating the causes of many of the hundreds of inherited forms of deafness’.<br /> Inherited conditions render one in a thousand children deaf at birth, and cause as many again to become deaf before maturity, leading to delay or failure in the acquisition of speech, and frequently to disadvantages in communication and learning. Genetic anomalies also contribute to many age-related and progressive forms of hearing loss. About one-tenth of the population in the developed world suffers from significant hearing impairment, which has an enormous impact on individuals and on society.<br /> Karen Steel and Christine Petit are at the forefront of efforts to understand the molecular mechanisms of the specialised hair cells in the inner ear, whose extraordinary sensitivity to mechanical stimulation underpins the senses of hearing and balance. These two researchers, at the peak of their productivity and influence, are international leaders in the field of hereditary deafness.<br /> Each has brought special skill to this challenging area of research. Their approaches have been complementary. Karen Steel has worked upwards, employing elegant and exhaustive study of mutations in mice and their functional consequences to illuminate human disorders. Christine Petit has started with the genetic analysis of patients, subsequently investigating the role of the identified genes in animal model systems.<br /> Professor Colin Blakemore, Oxford University, Chairman of the Selection Committee said: ‘Together, the work of these two Europeans scientists illustrates the value and power of interdisciplinary approaches in neuroscience, and the way in which cutting-edge fundamental research is needed to understand complex clinical problems and to accelerate benefit for patients’.......’We are delighted that The Brain Prize for the best of European neuroscience goes, in its second year, to two<br /> Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark<br /> Tel. +45 3917 8240 <a href="mailto:info@thebrainprize.org">info@thebrainprize.org</a> www.thebrainprize.org<br /> 12 March 2012<br /> women scientists. We are sure that the award will be applauded by female researchers around the world, and by all those who are concerned that young women are given every encouragement to consider careers in science’<br /> The prize lectures and award ceremony will take place 9th May in Copenhagen, Denmark. The Prize will be presented by Her Majesty the Queen.<br /> Bios: Christine Petit, Professor at College de France, holding the Chair of Genetics and Cellular Physiology, head of the Genetics and Physiology of Hearing laboratory at the Institut Pasteur in Paris also affiliated to INSERM, is a geneticist and a neurobiologist. She conceived and pioneered the genetic strategy to assess the molecular mechanisms underlying the cochlear differentiation and physiology. She developed this genetic approach in humans, by succeeding to overcome the difficulties specific to linkage analysis for deafness. She thereby mapped to human chromosomes the first two genes responsible for hereditary congenital deafness. She identified the causative genes for about 20 inherited forms of deafness, initially by an innovative candidate gene approach. Together with her colleagues, she also unraveled the roles of most of the proteins encoded by these genes, namely in the sensory hair cells, their stimulating gel, and the supporting cells, by multidisciplinary studies of engineered mouse models. Her work shed light on the functions mediated through various fibrous links within the hair bundle, the mechanoreceptive structure to sound. Her work on Usher syndrome (deafness, blindness), demonstrated that all Usher 1 proteins as well as all Usher 2 proteins form protein networks enabling the links they form to shape the hair bundle. She also identified some Usher1 proteins as components of the mechanotransduction machinery. Christine Petit’s discoveries have already had a significant impact on medical practice, with respect to diagnosis, genetic counseling and therapeutic decisions by indicating the potential benefit of cochlear implants and hearing aids for patients.<br /> Karen Steel, Professor and Principal Investigator for the Genetics of Deafness and founder of the Mouse Genetics Programme at the Wellcome Trust Sanger Institute, Hinxton, near Cambridge, UK, has pioneered the use of mouse models, starting with her painstaking description of the characteristics of mutant mice with disorders of balance and hearing. Her early work on cochlear function and hair cell degeneration in the mutant deafness mouse led to identification of the gene called Tmc1, the human homologue of which is mutated in several forms of hereditary deafness. She and her colleagues went on to identify causative genes in nearly 30 forms of hearing disorder in mice, most of which have been linked to human conditions. In particular, she described the genes for myosin-7a and cadherin-23, which are key components in the transduction mechanism in hair cells, and mutations of which underlie forms of Usher Syndrome. Karen Steel is internationally recognized for her generous and altruistic approach to science. Working with a consortium of European researchers, she has established, catalogued and made freely available to other researchers<br /> several hundred mouse mutant lines, which have facilitated research in several areas of neuroscience around the world.<br /> About the Brain Prize The Brain Prize - € 1 million is awarded by Grete Lundbeck European Brain Research Foundation, a charitable, non-profit organization.<br /> The Brain Prize is a personal prize awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European neuroscience.<br /> For more information please contact:<br /> Kim Krogsgaard, MD, DMSc or Director Mobile: +45 2014 8384 Phone: +45 3917 8240 <a href="mailto:kk@thebrainprize.org">kk@thebrainprize.org</a><br /> Nils Axelsen, MD, DMsc Chairman Mobile: +45 40548646<br /> Grete Lundbeck European Brain Research Foundation Ole Maaløes Vej 3 2200 N Copenhagen<br /> Denmark<br /> www.thebrainprize.org</p><p><a href="http://biologictube.dk/photo/4959161/brain-prize-winners-2012-karen"><img src="http://biologictube.dk/4959050/4959161/221a778e8530641df57b207fd7d2b4ab/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/4959161 Sun, 06 May 2012 13:44:37 GMT Brain Prize Winners 2012 Karen Steel and Christine Petit The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel: ‘for their unique, world-leading contributions to our understanding of the genetic regulation of the development and functioning of the ear, and for elucidating the causes of many of the hundreds of inherited forms of deafness’. Inherited conditions render one in a thousand children deaf at birth, and cause as many again to become deaf before maturity, leading to delay or failure in the acquisition of speech, and frequently to disadvantages in communication and learning. Genetic anomalies also contribute to many age-related and progressive forms of hearing loss. About one-tenth of the population in the developed world suffers from significant hearing impairment, which has an enormous impact on individuals and on society. Karen Steel and Christine Petit are at the forefront of efforts to understand the molecular mechanisms of the specialised hair cells in the inner ear, whose extraordinary sensitivity to mechanical stimulation underpins the senses of hearing and balance. These two researchers, at the peak of their productivity and influence, are international leaders in the field of hereditary deafness. Each has brought special skill to this challenging area of research. Their approaches have been complementary. Karen Steel has worked upwards, employing elegant and exhaustive study of mutations in mice and their functional consequences to illuminate human disorders. Christine Petit has started with the genetic analysis of patients, subsequently investigating the role of the identified genes in animal model systems. Professor Colin Blakemore, Oxford University, Chairman of the Selection Committee said: ‘Together, the work of these two Europeans scientists illustrates the value and power of interdisciplinary approaches in neuroscience, and the way in which cutting-edge fundamental research is needed to understand complex clinical problems and to accelerate benefit for patients’.......’We are delighted that The Brain Prize for the best of European neuroscience goes, in its second year, to two Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark Tel. +45 3917 8240 info@thebrainprize.org www.thebrainprize.org 12 March 2012 women scientists. We are sure that the award will be applauded by female researchers around the world, and by all those who are concerned that young women are given every encouragement to consider careers in science’ The prize lectures and award ceremony will take place 9th May in Copenhagen, Denmark. The Prize will be presented by Her Majesty the Queen. Bios: Christine Petit, Professor at College de France, holding the Chair of Genetics and Cellular Physiology, head of the Genetics and Physiology of Hearing laboratory at the Institut Pasteur in Paris also affiliated to INSERM, is a geneticist and a neurobiologist. She conceived and pioneered the genetic strategy to assess the molecular mechanisms underlying the cochlear differentiation and physiology. She developed this genetic approach in humans, by succeeding to overcome the difficulties specific to linkage analysis for deafness. She thereby mapped to human chromosomes the first two genes responsible for hereditary congenital deafness. She identified the causative genes for about 20 inherited forms of deafness, initially by an innovative candidate gene approach. Together with her colleagues, she also unraveled the roles of most of the proteins encoded by these genes, namely in the sensory hair cells, their stimulating gel, and the supporting cells, by multidisciplinary studies of engineered mouse models. Her work shed light on the functions mediated through various fibrous links within the hair bundle, the mechanoreceptive structure to sound. Her work on Usher syndrome (deafness, blindness), demonstrated that all Usher 1 proteins as well as all Usher 2 proteins form protein networks enabling the links they form to shape the hair bundle. She also identified some Usher1 proteins as components of the mechanotransduction machinery. Christine Petit’s discoveries have already had a significant impact on medical practice, with respect to diagnosis, genetic counseling and therapeutic decisions by indicating the potential benefit of cochlear implants and hearing aids for patients. Karen Steel, Professor and Principal Investigator for the Genetics of Deafness and founder of the Mouse Genetics Programme at the Wellcome Trust Sanger Institute, Hinxton, near Cambridge, UK, has pioneered the use of mouse models, starting with her painstaking description of the characteristics of mutant mice with disorders of balance and hearing. Her early work on cochlear function and hair cell degeneration in the mutant deafness mouse led to identification of the gene called Tmc1, the human homologue of which is mutated in several forms of hereditary deafness. She and her colleagues went on to identify causative genes in nearly 30 forms of hearing disorder in mice, most of which have been linked to human conditions. In particular, she described the genes for myosin-7a and cadherin-23, which are key components in the transduction mechanism in hair cells, and mutations of which underlie forms of Usher Syndrome. Karen Steel is internationally recognized for her generous and altruistic approach to science. Working with a consortium of European researchers, she has established, catalogued and made freely available to other researchers several hundred mouse mutant lines, which have facilitated research in several areas of neuroscience around the world. About the Brain Prize The Brain Prize - € 1 million is awarded by Grete Lundbeck European Brain Research Foundation, a charitable, non-profit organization. The Brain Prize is a personal prize awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European neuroscience. For more information please contact: Kim Krogsgaard, MD, DMSc or Director Mobile: +45 2014 8384 Phone: +45 3917 8240 kk@thebrainprize.org Nils Axelsen, MD, DMsc Chairman Mobile: +45 40548646 Grete Lundbeck European Brain Research Foundation Ole Maaløes Vej 3 2200 N Copenhagen Denmark www.thebrainprize.org The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel: ‘for their unique, world-leading contributions to our understanding of the genetic regulation of... Welcome to the BioLogicTube 03:28 <p>The Grete Lundbeck European Brain Research Foundation has announced that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel:<br /> ‘for their unique, world-leading contributions to our understanding of the genetic regulation of the development and functioning of the ear, and for elucidating the causes of many of the hundreds of inherited forms of deafness’.<br /> Inherited conditions render one in a thousand children deaf at birth, and cause as many again to become deaf before maturity, leading to delay or failure in the acquisition of speech, and frequently to disadvantages in communication and learning. Genetic anomalies also contribute to many age-related and progressive forms of hearing loss. About one-tenth of the population in the developed world suffers from significant hearing impairment, which has an enormous impact on individuals and on society.<br /> Karen Steel and Christine Petit are at the forefront of efforts to understand the molecular mechanisms of the specialised hair cells in the inner ear, whose extraordinary sensitivity to mechanical stimulation underpins the senses of hearing and balance. These two researchers, at the peak of their productivity and influence, are international leaders in the field of hereditary deafness.<br /> Each has brought special skill to this challenging area of research. Their approaches have been complementary. Karen Steel has worked upwards, employing elegant and exhaustive study of mutations in mice and their functional consequences to illuminate human disorders. Christine Petit has started with the genetic analysis of patients, subsequently investigating the role of the identified genes in animal model systems.<br /> Professor Colin Blakemore, Oxford University, Chairman of the Selection Committee said: ‘Together, the work of these two Europeans scientists illustrates the value and power of interdisciplinary approaches in neuroscience, and the way in which cutting-edge fundamental research is needed to understand complex clinical problems and to accelerate benefit for patients’.......’We are delighted that The Brain Prize for the best of European neuroscience goes, in its second year, to two<br /> Ole Maaløes Vej 3 DK-2200 Copenhagen N Denmark<br /> Tel. +45 3917 8240 <a href="mailto:info@thebrainprize.org">info@thebrainprize.org</a> www.thebrainprize.org<br /> 12 March 2012<br /> women scientists. We are sure that the award will be applauded by female researchers around the world, and by all those who are concerned that young women are given every encouragement to consider careers in science’<br /> The prize lectures and award ceremony will take place 9th May in Copenhagen, Denmark. The Prize will be presented by Her Majesty the Queen.<br /> Bios: Christine Petit, Professor at College de France, holding the Chair of Genetics and Cellular Physiology, head of the Genetics and Physiology of Hearing laboratory at the Institut Pasteur in Paris also affiliated to INSERM, is a geneticist and a neurobiologist. She conceived and pioneered the genetic strategy to assess the molecular mechanisms underlying the cochlear differentiation and physiology. She developed this genetic approach in humans, by succeeding to overcome the difficulties specific to linkage analysis for deafness. She thereby mapped to human chromosomes the first two genes responsible for hereditary congenital deafness. She identified the causative genes for about 20 inherited forms of deafness, initially by an innovative candidate gene approach. Together with her colleagues, she also unraveled the roles of most of the proteins encoded by these genes, namely in the sensory hair cells, their stimulating gel, and the supporting cells, by multidisciplinary studies of engineered mouse models. Her work shed light on the functions mediated through various fibrous links within the hair bundle, the mechanoreceptive structure to sound. Her work on Usher syndrome (deafness, blindness), demonstrated that all Usher 1 proteins as well as all Usher 2 proteins form protein networks enabling the links they form to shape the hair bundle. She also identified some Usher1 proteins as components of the mechanotransduction machinery. Christine Petit’s discoveries have already had a significant impact on medical practice, with respect to diagnosis, genetic counseling and therapeutic decisions by indicating the potential benefit of cochlear implants and hearing aids for patients.<br /> Karen Steel, Professor and Principal Investigator for the Genetics of Deafness and founder of the Mouse Genetics Programme at the Wellcome Trust Sanger Institute, Hinxton, near Cambridge, UK, has pioneered the use of mouse models, starting with her painstaking description of the characteristics of mutant mice with disorders of balance and hearing. Her early work on cochlear function and hair cell degeneration in the mutant deafness mouse led to identification of the gene called Tmc1, the human homologue of which is mutated in several forms of hereditary deafness. She and her colleagues went on to identify causative genes in nearly 30 forms of hearing disorder in mice, most of which have been linked to human conditions. In particular, she described the genes for myosin-7a and cadherin-23, which are key components in the transduction mechanism in hair cells, and mutations of which underlie forms of Usher Syndrome. Karen Steel is internationally recognized for her generous and altruistic approach to science. Working with a consortium of European researchers, she has established, catalogued and made freely available to other researchers<br /> several hundred mouse mutant lines, which have facilitated research in several areas of neuroscience around the world.<br /> About the Brain Prize The Brain Prize - € 1 million is awarded by Grete Lundbeck European Brain Research Foundation, a charitable, non-profit organization.<br /> The Brain Prize is a personal prize awarded to one or more scientists who have distinguished themselves by an outstanding contribution to European neuroscience.<br /> For more information please contact:<br /> Kim Krogsgaard, MD, DMSc or Director Mobile: +45 2014 8384 Phone: +45 3917 8240 <a href="mailto:kk@thebrainprize.org">kk@thebrainprize.org</a><br /> Nils Axelsen, MD, DMsc Chairman Mobile: +45 40548646<br /> Grete Lundbeck European Brain Research Foundation Ole Maaløes Vej 3 2200 N Copenhagen<br /> Denmark<br /> www.thebrainprize.org</p><p><a href="http://biologictube.dk/photo/4959161/brain-prize-winners-2012-karen"><img src="http://biologictube.dk/4959050/4959161/221a778e8530641df57b207fd7d2b4ab/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> BioLogicMedia Bjørn Christine Karen Petit Steel Vidø and brain daniel eugen-olsen frank jesper kim krogsgaard lone lundbeck neuroscience prize http://biologictube.dk/photo/3548165/frank-tacke-md-phd-university <p>Dr Tacke discuss suPAR results at the 2’nd International suPAR Symposium</p> <p>Crit Care. 2011;15(1):R63. Epub 2011 Feb 16.<br /> Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.<br /> Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F.<br /> SourceDepartment of Medicine III, RWTH-University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.</p> <p>Abstract<br /> INTRODUCTION: suPAR is the soluble form of the urokinase plasminogen activator receptor (uPAR), which is expressed in various immunologically active cells. High suPAR serum concentrations are suggested to reflect the activation of the immune system in circumstances of inflammation and infection, and have been associated with increased mortality in different populations of non-intensive care patients. In this study we sequentially analyzed suPAR serum concentrations within the first week of intensive care in a large cohort of well characterized intensive care unit (ICU) patients, in order to investigate potential regulatory mechanisms and evaluate the prognostic significance in critically ill patients.</p> <p>METHODS: A total of 273 patients (197 with sepsis, 76 without sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU), on Day 3 and Day 7, and compared to 43 healthy controls. Clinical data, various laboratory parameters as well as investigational inflammatory cytokine profiles were assessed. Patients were followed for approximately one year.</p> <p>RESULTS: Upon admission to the ICU suPAR serum concentrations were elevated in critically ill patients as compared with healthy controls. In sepsis patients suPAR levels were higher than in non-sepsis patients (with or without systemic inflammatory response syndrome (SIRS)). During the first week after admission to the ICU serum suPAR concentrations remained stably elevated. suPAR serum concentrations measured upon admission were closely and independently correlated to various laboratory parameters, specifically biomarkers of inflammation (tumor necrosis factor (TNF), C-reactive protein (CRP)), hepatic and renal dysfunction. High suPAR levels at admission and at Day 3 were a strong independent predictor for both ICU and long-term mortality in critically ill patients.</p> <p>CONCLUSIONS: In sepsis and non-sepsis patients suPAR serum concentrations are increased upon admission to the ICU, likely reflecting the activation state of the immune system, and remain stably elevated in the initial course of treatment. Low suPAR levels are a positive predictor of ICU- and overall survival in critically ill patients, including sepsis and non-sepsis patients. Aside from its value as a promising new prognostic biomarker, both experimental and clinical studies are required in order to understand the specific effects and regulatory mechanisms of suPAR in SIRS and sepsis, and may reveal new therapeutic options.</p> <p>Officel welcome words at the conference:<br /> Dear Colleagues</p> <p>On behalf of the scientific committee, it is my pleasure to welcome you to “The 2nd International Conference on suPAR” taking place in early spring 2011 at the Danish National Museum in Copenhagen.<br /> <br /> <br /> <br /> The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.</p> <p>But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do.</p> <p>A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker.</p> <p>We look forward to sharing these exciting data and to welcome you to the heart of Copenhagen<br /> <br /> <br /> Sincerely</p> <p>Jesper Eugen-Olsen, PhD, conference chairman<br /> Laboratory research director,<br /> Copenhagen University Hospital, Hvidovre<br /> <br /> <br /> <br /> Purpose and Scope<br /> <br /> <br /> <br /> The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.<br /> <br /> <br /> <br /> The symposium aim is to bring together researchers, users and other persons to discuss the features and potential usability of the suPAR protein as a biomarker and will:<br /> <br /> <br /> <br /> ◦Provide a forum to learn about new findings and current suPAR studies<br /> ◦Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker<br /> ◦Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements<br /> ◦Facilitate foundation for international net-working</p><p><a href="http://biologictube.dk/photo/3548165/frank-tacke-md-phd-university"><img src="http://biologictube.dk/1984075/3548165/bdb361a3245a07f851858d43dbc0fc48/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/3548165 Tue, 11 Oct 2011 12:48:22 GMT Frank Tacke, MD, PhD, University Hopsital Achen, Germany: Diagnostic and... Dr Tacke discuss suPAR results at the 2’nd International suPAR Symposium Crit Care. 2011;15(1):R63. Epub 2011 Feb 16. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. SourceDepartment of Medicine III, RWTH-University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany. Abstract INTRODUCTION: suPAR is the soluble form of the urokinase plasminogen activator receptor (uPAR), which is expressed in various immunologically active cells. High suPAR serum concentrations are suggested to reflect the activation of the immune system in circumstances of inflammation and infection, and have been associated with increased mortality in different populations of non-intensive care patients. In this study we sequentially analyzed suPAR serum concentrations within the first week of intensive care in a large cohort of well characterized intensive care unit (ICU) patients, in order to investigate potential regulatory mechanisms and evaluate the prognostic significance in critically ill patients. METHODS: A total of 273 patients (197 with sepsis, 76 without sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU), on Day 3 and Day 7, and compared to 43 healthy controls. Clinical data, various laboratory parameters as well as investigational inflammatory cytokine profiles were assessed. Patients were followed for approximately one year. RESULTS: Upon admission to the ICU suPAR serum concentrations were elevated in critically ill patients as compared with healthy controls. In sepsis patients suPAR levels were higher than in non-sepsis patients (with or without systemic inflammatory response syndrome (SIRS)). During the first week after admission to the ICU serum suPAR concentrations remained stably elevated. suPAR serum concentrations measured upon admission were closely and independently correlated to various laboratory parameters, specifically biomarkers of inflammation (tumor necrosis factor (TNF), C-reactive protein (CRP)), hepatic and renal dysfunction. High suPAR levels at admission and at Day 3 were a strong independent predictor for both ICU and long-term mortality in critically ill patients. CONCLUSIONS: In sepsis and non-sepsis patients suPAR serum concentrations are increased upon admission to the ICU, likely reflecting the activation state of the immune system, and remain stably elevated in the initial course of treatment. Low suPAR levels are a positive predictor of ICU- and overall survival in critically ill patients, including sepsis and non-sepsis patients. Aside from its value as a promising new prognostic biomarker, both experimental and clinical studies are required in order to understand the specific effects and regulatory mechanisms of suPAR in SIRS and sepsis, and may reveal new therapeutic options. Officel welcome words at the conference: Dear Colleagues On behalf of the scientific committee, it is my pleasure to welcome you to “The 2nd International Conference on suPAR” taking place in early spring 2011 at the Danish National Museum in Copenhagen. The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes. But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do. A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker. We look forward to sharing these exciting data and to welcome you to the heart of Copenhagen Sincerely Jesper Eugen-Olsen, PhD, conference chairman Laboratory research director, Copenhagen University Hospital, Hvidovre Purpose and Scope The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications. The symposium aim is to bring together researchers, users and other persons to discuss the features and potential usability of the suPAR protein as a biomarker and will: ◦Provide a forum to learn about new findings and current suPAR studies ◦Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker ◦Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements ◦Facilitate foundation for international net-working Dr Tacke discuss suPAR results at the 2’nd International suPAR Symposium Crit Care. 2011;15(1):R63. Epub 2011 Feb 16. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the... Welcome to the BioLogicTube 16:58 <p>Dr Tacke discuss suPAR results at the 2’nd International suPAR Symposium</p> <p>Crit Care. 2011;15(1):R63. Epub 2011 Feb 16.<br /> Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.<br /> Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F.<br /> SourceDepartment of Medicine III, RWTH-University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.</p> <p>Abstract<br /> INTRODUCTION: suPAR is the soluble form of the urokinase plasminogen activator receptor (uPAR), which is expressed in various immunologically active cells. High suPAR serum concentrations are suggested to reflect the activation of the immune system in circumstances of inflammation and infection, and have been associated with increased mortality in different populations of non-intensive care patients. In this study we sequentially analyzed suPAR serum concentrations within the first week of intensive care in a large cohort of well characterized intensive care unit (ICU) patients, in order to investigate potential regulatory mechanisms and evaluate the prognostic significance in critically ill patients.</p> <p>METHODS: A total of 273 patients (197 with sepsis, 76 without sepsis) were studied prospectively upon admission to the medical intensive care unit (ICU), on Day 3 and Day 7, and compared to 43 healthy controls. Clinical data, various laboratory parameters as well as investigational inflammatory cytokine profiles were assessed. Patients were followed for approximately one year.</p> <p>RESULTS: Upon admission to the ICU suPAR serum concentrations were elevated in critically ill patients as compared with healthy controls. In sepsis patients suPAR levels were higher than in non-sepsis patients (with or without systemic inflammatory response syndrome (SIRS)). During the first week after admission to the ICU serum suPAR concentrations remained stably elevated. suPAR serum concentrations measured upon admission were closely and independently correlated to various laboratory parameters, specifically biomarkers of inflammation (tumor necrosis factor (TNF), C-reactive protein (CRP)), hepatic and renal dysfunction. High suPAR levels at admission and at Day 3 were a strong independent predictor for both ICU and long-term mortality in critically ill patients.</p> <p>CONCLUSIONS: In sepsis and non-sepsis patients suPAR serum concentrations are increased upon admission to the ICU, likely reflecting the activation state of the immune system, and remain stably elevated in the initial course of treatment. Low suPAR levels are a positive predictor of ICU- and overall survival in critically ill patients, including sepsis and non-sepsis patients. Aside from its value as a promising new prognostic biomarker, both experimental and clinical studies are required in order to understand the specific effects and regulatory mechanisms of suPAR in SIRS and sepsis, and may reveal new therapeutic options.</p> <p>Officel welcome words at the conference:<br /> Dear Colleagues</p> <p>On behalf of the scientific committee, it is my pleasure to welcome you to “The 2nd International Conference on suPAR” taking place in early spring 2011 at the Danish National Museum in Copenhagen.<br /> <br /> <br /> <br /> The 1st International conference on suPAR” in 2003 shared findings on suPAR as a marker of disease progression and survival in HIV and TB infected. Since then, suPAR has been broadly applied to a range of diseases and the same picture is emerging. An elevated suPAR is associated with a negative prognosis independent of disease. Even among the general population, an elevated suPAR has recently been shown to be associated with increased risk of diseases such as cardiovascular disease, cancer and Type 2 Diabetes.</p> <p>But what does an elevated suPAR reflect? The suPAR level is positively correlated with markers of inflammation and immune activation such as CRP (hsCRP), TNF-a and white blood cell counts. Thus, suPAR may be a novel marker of inflammation, and increased inflammation has in recent years been suggested as a disease driving mechanism. Nevertheless, suPAR remains associated with disease endpoints after the adjustment of other inflammatory markers and is less related to metabolic variables than CRP. Thus suPAR may reflect another aspect of inflammation than the classical markers do.</p> <p>A large number of studies are currently investigating the role of suPAR in a wide variety of conditions, and this conference will bring forward the newest data which will further enlighten the role and possible applications of this biomarker.</p> <p>We look forward to sharing these exciting data and to welcome you to the heart of Copenhagen<br /> <br /> <br /> Sincerely</p> <p>Jesper Eugen-Olsen, PhD, conference chairman<br /> Laboratory research director,<br /> Copenhagen University Hospital, Hvidovre<br /> <br /> <br /> <br /> Purpose and Scope<br /> <br /> <br /> <br /> The suPAR (soluble urokinase Plasminogen Activator Receptor) protein is a relatively new biomarker which has ability to predict severity of illness and mortality. The prognostic value of suPAR has been described in published studies in recent years and is currently being tested in several health care applications.<br /> <br /> <br /> <br /> The symposium aim is to bring together researchers, users and other persons to discuss the features and potential usability of the suPAR protein as a biomarker and will:<br /> <br /> <br /> <br /> ◦Provide a forum to learn about new findings and current suPAR studies<br /> ◦Host a scientific community discussion on the new opportunities that exist with a prognostic biomarker<br /> ◦Hear from the delegates what questions, feed-back and ideas for suPAR applications and user requirements<br /> ◦Facilitate foundation for international net-working</p><p><a href="http://biologictube.dk/photo/3548165/frank-tacke-md-phd-university"><img src="http://biologictube.dk/1984075/3548165/bdb361a3245a07f851858d43dbc0fc48/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> ICU- Low a activation and are course critically elevated ill immune in including initial levels non-sepsis of overall patients positive predictor remain sepsis stably state suPAR survival system the treatment. http://biologictube.dk/photo/3250248/bgi-opening-2012 <p>On March 3, 2011, a new research center--Danish Platform for Large-scale Sequencing and Bioinformaticsis to be funded with DKK 170 million by Danish National Advanced Technology Foundation (DKK 84 million), BGI (DKK 60 million) and other partners. This center aims to support development of cancer vaccines and Danish genome research. There are two projects in this platform: One project is to identify previously unknown pathogens that will lead to the development and patenting of commercial vaccines. The second is to establish a unique catalogue of the millions of variations in Danes' DNA. BGI Europe (an overseas branch of BGI) situated at Copenhagen Bio Science Park (COBIS) will play an important role in the disease prevention and genome research.</p> <p>The following article is quoted from the news release of University of Copenhagen:<br /> http://news.ku.dk/all_news/2011/2011.3/majorgranttosupportdevelopmentofcancervaccine/</p><p><a href="http://biologictube.dk/photo/3250248/bgi-opening-2012"><img src="http://biologictube.dk/1984072/3250248/0010c13a6a727da29dd6d261a8ee11bf/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/3250248 Mon, 12 Sep 2011 23:35:05 GMT BGI opening 2012 On March 3, 2011, a new research center--Danish Platform for Large-scale Sequencing and Bioinformaticsis to be funded with DKK 170 million by Danish National Advanced Technology Foundation (DKK 84 million), BGI (DKK 60 million) and other partners. This center aims to support development of cancer vaccines and Danish genome research. There are two projects in this platform: One project is to identify previously unknown pathogens that will lead to the development and patenting of commercial vaccines. The second is to establish a unique catalogue of the millions of variations in Danes' DNA. BGI Europe (an overseas branch of BGI) situated at Copenhagen Bio Science Park (COBIS) will play an important role in the disease prevention and genome research. The following article is quoted from the news release of University of Copenhagen: http://news.ku.dk/all_news/2011/2011.3/majorgranttosupportdevelopmentofcancervaccine/ On March 3, 2011, a new research center--Danish Platform for Large-scale Sequencing and Bioinformaticsis to be funded with DKK 170 million by Danish National Advanced Technology Foundation (DKK 84 million), BGI (DKK 60 million) and other partners.... Welcome to the BioLogicTube 01:04 <p>On March 3, 2011, a new research center--Danish Platform for Large-scale Sequencing and Bioinformaticsis to be funded with DKK 170 million by Danish National Advanced Technology Foundation (DKK 84 million), BGI (DKK 60 million) and other partners. This center aims to support development of cancer vaccines and Danish genome research. There are two projects in this platform: One project is to identify previously unknown pathogens that will lead to the development and patenting of commercial vaccines. The second is to establish a unique catalogue of the millions of variations in Danes' DNA. BGI Europe (an overseas branch of BGI) situated at Copenhagen Bio Science Park (COBIS) will play an important role in the disease prevention and genome research.</p> <p>The following article is quoted from the news release of University of Copenhagen:<br /> http://news.ku.dk/all_news/2011/2011.3/majorgranttosupportdevelopmentofcancervaccine/</p><p><a href="http://biologictube.dk/photo/3250248/bgi-opening-2012"><img src="http://biologictube.dk/1984072/3250248/0010c13a6a727da29dd6d261a8ee11bf/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> 2012 Advanced BGI Bioinformaticsis Foundation Large-scale National Sequencing Technology and center h new opening research